Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
14.35
-0.19 (-1.31%)
Apr 13, 2026, 10:40 AM EDT - Market open
Cullinan Therapeutics Employees
Cullinan Therapeutics had 109 employees as of December 31, 2025. The number of employees decreased by 2 or -1.80% compared to the previous year.
Employees
109
Change (1Y)
-2
Growth (1Y)
-1.80%
Revenue / Employee
n/a
Profits / Employee
-$2,017,239
Market Cap
868.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 109 | -2 | -1.80% | 109 | 0 |
| Dec 31, 2024 | 111 | 26 | 30.59% | 111 | 0 |
| Dec 31, 2023 | 85 | 23 | 37.10% | 85 | 0 |
| Dec 31, 2022 | 62 | 31 | 100.00% | 62 | 0 |
| Mar 31, 2022 | 37 | 13 | 54.17% | 37 | 0 |
| Dec 31, 2021 | 31 | 7 | 29.17% | 31 | 0 |
| Sep 30, 2021 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2021 | 28 | 11 | 64.71% | 28 | 0 |
| Mar 31, 2021 | 24 | 7 | 41.18% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Xencor | 260 |
| Omeros | 175 |
| Janux Therapeutics | 109 |
| Theravance Biopharma | 90 |
| Vor Biopharma | 76 |
| Jade Biosciences | 55 |
| Compass Therapeutics | 39 |
CGEM News
- 4 weeks ago - Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones - GlobeNewsWire
- 4 months ago - Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting - GlobeNewsWire
- 4 months ago - Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 5 months ago - Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - PRNewsWire